Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Association of serum Sestrin-2 level with insulin resistance, metabolic syndrome, and diabetic nephropathy in patients with type 2 diabetes

The Egyptian Journal of Internal Medicine volume 31, pages 107–114 (2019)Cite this article

Abstract

Background

The aim of the study was to evaluate the relationship between serum Sestrin2, Insulin resistance (IR), metabolic syndrome (MetS), and diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM).

Patients and methods

The study group consisted of 155 patients with T2DM who were recruited and evaluated for DN. IR was evaluated by the homeostasis model assessment-insulin resistance (HOMA-IR). Sestrin2 levels were determined by enzyme-linked immunosorbent assay.

Results

Serum Sestrin2 levels showed significant positive correlations with tumor necrosis factor-α (r=0.247, P=0.018), triglycerides (r=0.178, P=0.021), total cholesterol (r=0.33, P=0.007), fasting c-peptide (r=0.164, P=0.035), and systolic blood pressure (r=0.171, P=0.041). A significant negative correlation was found between Sestrin2 levels and serum adiponectin (r=0.247, P=0.018). Also, Sestrin2 levels were positively correlated HOMA-IR (r=0.188, P=0.026). There was a progressive significant increase of mean HOMA-IR through Sestrin2 tertiles (P=0.001). A significant increase of mean serum Sestrin2 levels was found in relation to the presence of DN or MetS.

Conclusion

Serum Sestrin2 levels are significantly associated with IR, MetS, and DN in patients with T2DM.

References

  1. Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complications 2013; 27:526–530.

    Article  Google Scholar 

  2. Rask-Madsen C, Li Q, Freund B, Feather D, Abramov R, Wu I-H, et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2010; 11:379–389.

    Article  CAS  Google Scholar 

  3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058–1070.

    Article  CAS  Google Scholar 

  4. Park Y-M., Zhang J, Steck SE, Fung TT, Hazlett LJ, Han K, et al. Obesity mediates the association between mediterranean diet consumption and insulin resistance and inflammation in US adults-3. J Nutr 2017; 147:563–571.

    Article  CAS  Google Scholar 

  5. Huh JH, Yadav D, Kim JS, Son J-W., Choi E, Kim SH, et al. An association of metabolic syndrome and chronic kidney disease from a 10-year prospective cohort study. Metabolism 2017; 67:54–61.

    Article  CAS  Google Scholar 

  6. Guo R, Nair S, Zhang Y, Ren J. Adiponectin deficiency rescues high-fat diet-induced hepatic injury, apoptosis and autophagy loss despite persistent steatosis. Int J Obes (Lond) 2017; 41:1403–1412.

    Article  CAS  Google Scholar 

  7. Cho S-A., Joo HJ, Cho J-Y., Lee SH, Park JH, Hong SJ, et al. Visceral fat area and serum adiponectin level predict the development of metabolic syndrome in a community-based asymptomatic population. PloS One 2017; 12:e0169289.

    Article  Google Scholar 

  8. Lee JH, Budanov AV, Karin M. Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metab 2013; 18:792–801.

    Article  CAS  Google Scholar 

  9. Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL, Park H-W, et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab 2012; 16:311–321.

    Article  CAS  Google Scholar 

  10. Lee JH, Budanov AV, Park EJ, Birse R, Kim TE, Perkins GA, et al. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 2010; 327:1223–1228.

    Article  CAS  Google Scholar 

  11. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008; 134:451–460.

    Article  CAS  Google Scholar 

  12. Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.

    Article  Google Scholar 

  13. Chung HS, Roh E, Hong S-H., Kim JA, Lee Y-B., Baik SH, et al. Association of serum Sestrin2 level with metabolic risk factors in newly diagnosed drug-naïve type 2. Diabetes Res Clin Pract 2018; 144:34–41.

    Article  CAS  Google Scholar 

  14. Nourbakhsh M, Sharifi R, Ghorbanhosseini SS, Javad A, Ahmadpour F, Razzaghy Azar M, et al. Evaluation of plasma TRB3 and Sestrin 2 levels in obese and normal-weight children. Child Obes 2017; 13:409–414.

    Article  Google Scholar 

  15. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006; 26:871–876.

    Article  CAS  Google Scholar 

  16. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42:231–234.

    Article  CAS  Google Scholar 

  17. Adamczak M, Wicek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16:72–75.

    Article  CAS  Google Scholar 

  18. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85–89.

    Article  CAS  Google Scholar 

  19. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730–1737.

    Article  CAS  Google Scholar 

  20. Kim J-Y, Ann SV, Yoon J-H, Koh S-B, Yoon J, Yoo B-S, et al. Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study. Diabetes Care 2013; 36:1547–1553.

    Article  CAS  Google Scholar 

  21. King GA, Deemer SE, Thompson DL. Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women. Acta Diabetol 2012; 49:41–49.

    Article  CAS  Google Scholar 

  22. Nakashima R, Yamane K, Kamei N, Nakanishi S, Kohno N. Low serum levels of total and high-molecular-weight adiponectin predict the development of metabolic syndrome in Japanese-Americans. J Endocrinol Invest 2011; 34:615–619.

    CAS  PubMed  Google Scholar 

  23. Kobayashi H, Nakamura T, Miyaoka K, Nishida M, Funahashi T, Yamashita S, et al. Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J 2001; 65:193–199.

    Article  CAS  Google Scholar 

  24. Martin M, Palaniappan LP, Kwan AC, Reaven GM, Reaven PD. Ethnic differences in the relationship between adiponectin and insulin sensitivity in South Asian and Caucasian women. Diabetes Care 2008; 31:798–801.

    Article  CAS  Google Scholar 

  25. Ferris W, Naran N, Crowther N, Rheeder P, Van der Merwe L, Chetty N. The relationship between insulin sensitivity and serum adiponectin levels in three population groups. Horm Metab Res 2005; 37:695–701.

    Article  CAS  Google Scholar 

  26. Kadowaki T, Sekikawa A, Okamura T, Takamiya T, Kashiwagi A, Zaky WR, et al. Higher levels of adiponectin in American than in Japanese men despite obesity. Metabolism 2006; 55:1561–1563.

    Article  CAS  Google Scholar 

  27. Inoue M, Yano M, Yamakado M, Maehata E, Suzuki S. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 2006; 55:1248–1254.

    Article  CAS  Google Scholar 

  28. Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, et al. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death Differ 2013; 20:611–619.

    Article  CAS  Google Scholar 

  29. Wang X, Yang C, Liu X, Yang P. The impact of microRNA-122 and its target gene Sestrin-2 on the protective effect of ghrelin in angiotensin II-induced cardiomyocyte apoptosis. RSC Adv 2018; 8:10107–10114.

    Article  CAS  Google Scholar 

  30. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25:971–976.

    Article  Google Scholar 

  31. Cnop M, Havel P, Utzschneider K, Carr D, Sinha M, Boyko E, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46:459–469.

    Article  CAS  Google Scholar 

  32. Steinberger J, Steffen L, Jacobs DR Jr, Moran A, Hong CP, Sinaiko AR. Relation of leptin to insulin resistance syndrome in children. Obes Res 2003; 11:1124–1130.

    Article  CAS  Google Scholar 

  33. Huang K, Lin R, Kormas N, Lee L, Chen C, Gill T, et al. Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int J Obes 2004; 28:470.

    Article  CAS  Google Scholar 

  34. Retnakaran R, Zinman B, Connelly PW, Harris SB, Hanley AJ. Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Pediatr 2006; 148:176–182.

    Article  Google Scholar 

  35. Platat C, Wagner A, Klumpp T, Schweitzer B, Simon C. Relationships of physical activity with metabolic syndrome features and low-grade inflammation in adolescents. Diabetologia 2006; 49:2078–2085.

    Article  CAS  Google Scholar 

  36. Kshatriya S, Liu K, Salah A, Szombathy T, Freeman RH, Reams GP, et al. Obesity hypertension: the regulatory role of leptin. Int J Hypertens 2011; 2011:270624.

    Article  Google Scholar 

  37. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007; 49:310–317.

    Article  CAS  Google Scholar 

  38. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121:2197–2209.

    Article  Google Scholar 

  39. Smeets B, Huber TB. Sestrin 2: a regulator of glomerular parietal epithelial cell phenotype. Am J Physiol Renal Physiol. 2014; 307:F798–F799.

    Article  CAS  Google Scholar 

  40. Inoki K, Huber TB. Mammalian target of rapamycin signaling in the podocyte. Curr Opin Nephrol Hypertens 2012; 21:251–257.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Endocrinology Unit, Faculty of Human Medicine, Zagazig University, Sharkyia Governorate, Zagazig City, 44519, Egypt

    Hazem M. EL-Ashmawy MD

  2. Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Azza M. Ahmed

Authors
  1. Hazem M. EL-Ashmawy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Azza M. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hazem M. EL-Ashmawy MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

EL-Ashmawy, H.M., Ahmed, A.M. Association of serum Sestrin-2 level with insulin resistance, metabolic syndrome, and diabetic nephropathy in patients with type 2 diabetes. Egypt J Intern Med 31, 107–114 (2019). https://doi.org/10.4103/ejim.ejim_85_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_85_18

Keywords